These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 9679209)

  • 41. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous magnesium for the treatment of cardiac arrhythmias.
    Arnold DJ
    Aust N Z J Med; 2000 Feb; 30(1):54-60. PubMed ID: 10800879
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug therapy for atrial fibrillation.
    Vardas PE; Kallergis EM
    Expert Opin Pharmacother; 2006 Jun; 7(9):1121-31. PubMed ID: 16732699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ; Markham A
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiarrhythmic drug therapy: new drugs and changing concepts.
    Reiser HJ; Sullivan ME
    Fed Proc; 1986 Jul; 45(8):2206-12. PubMed ID: 2873062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Basic concepts in cellular cardiac electrophysiology: Part II: Block of ion channels by antiarrhythmic drugs.
    Whalley DW; Wendt DJ; Grant AO
    Pacing Clin Electrophysiol; 1995 Sep; 18(9 Pt 1):1686-704. PubMed ID: 7491312
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perspectives on the current treatment of cardiac arrhythmias.
    Bigger JT
    Am J Cardiol; 1984 Aug; 54(4):2B-7B. PubMed ID: 6147081
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH; Decara JM
    Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calcium antagonists. Clinical use in the treatment of arrhythmias.
    Singh BN; Nademanee K; Baky SH
    Drugs; 1983 Feb; 25(2):125-53. PubMed ID: 6339197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of class III antiarrhythmic agents in maintaining sinus rhythm.
    Brachmann J
    Europace; 2000 Jul; 1 Suppl C():C10-5. PubMed ID: 11220519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. General principles of antiarrhythmic therapy for ventricular tachyarrhythmias.
    Landers MD; Reiter MJ
    Am J Cardiol; 1997 Oct; 80(8A):31G-44G. PubMed ID: 9354410
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical use of beta-blocker an as antiarrhythmic agent].
    Okazaki O; Akatsuka N
    Nihon Rinsho; 1996 Aug; 54(8):2117-24. PubMed ID: 8810786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atrial fibrillation and atrial flutter.
    Geraets DR; Kienzle MG
    Clin Pharm; 1993 Oct; 12(10):721-35; quiz 783-4. PubMed ID: 7903069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha D
    Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antiarrhythmic drugs in the present day].
    Allgaier R; Duncker D
    Inn Med (Heidelb); 2024 Aug; 65(8):762-769. PubMed ID: 39009875
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of drug therapy for sustained ventricular tachyarrhythmias.
    Mitchell LB
    Cardiol Clin; 2008 Aug; 26(3):405-18, vi. PubMed ID: 18538187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmacology of modern anti-arrhythmia drugs in therapy of supraventricular tachycardia].
    Honerjäger P; Schmidt G
    Z Gesamte Inn Med; 1993 Sep; 48(9):425-9. PubMed ID: 8212747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.